Bevacizumab (Avastin) - Revision history

Lazy at 08:22, 18 January 2025

2025-01-18T08:22:44Z

← Older revision		Revision as of 01:22, 18 January 2025
Line 1:		Line 1:
	{{TreatmentInfo		{{TreatmentInfo
	\|drug_name=~~Bevacizumab (Avastin)~~		\|drug_name=Procarbazine
	\|overview=Bevacizumab, sold under the brand name Avastin, is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF). By targeting VEGF, Avastin reduces the blood supply to tumors, which can slow their growth. It is FDA-approved for the treatment of recurrent glioblastoma and is often combined with other therapies to manage this aggressive cancer.		\|FDA_approval=Yes
	\|FDA_approval=Yes~~, for recurrent glioblastoma~~		\|used_for=Glioblastoma
	\|used_for=~~Management of recurrent glioblastoma and investigational use in newly diagnosed glioblastoma as part of combination therapies~~		\|clinical_trial_phase=Not specified
	\|clinical_trial_phase=~~Phase III for glioblastoma~~		\|common_side_effects=Hematological toxicity, nausea, and neurological effects
	\|common_side_effects=~~Hypertension, proteinuria, hemorrhage~~, ~~gastrointestinal perforation, thromboembolic events~~, and ~~wound healing complications~~		\|OS_with=Not specified
	\|OS_with=~~AVAglio trial: 16.8 months; RTOG trial: 15.7 months~~		\|usefulness_rating=3
	\|~~PFS_with~~=~~AVAglio trial: 10.6 months; RTOG trial: 10 months~~		\|notes=Combination of Temodar and procarbazine showed a high percentage of tumor regressions, suggesting effectiveness.
	\|~~OS_without~~=~~AVAglio trial: 16.7 months; RTOG trial: 16.1 months~~
	~~\|PFS_without=AVAglio trial: 6.2 months; RTOG trial: 7~~.~~3 months~~
	~~\|usefulness_rating=4~~
	~~\|links=~~
	~~\|toxicity_level=3~~
	\|treatment_category=Other Chemotherapy and Cancer Drugs		\|treatment_category=Other Chemotherapy and Cancer Drugs
	\|toxicity_explanation=~~Bevacizumab has a moderate toxicity profile~~. ~~While it can extend progression-free survival and improve quality of life in glioblastoma patients, it can cause significant~~ side effects~~. These include hypertension~~, ~~proteinuria~~, ~~bleeding~~, and ~~rare but severe complications like gastrointestinal perforation and thromboembolic events~~. ~~Regular monitoring and management of~~ side effects are ~~essential during treatment.~~		\|toxicity_level=4
	~~\|notes=Bevacizumab has shown efficacy in improving progression~~-~~free survival in glioblastoma patients but does not significantly extend overall survival when compared~~ to ~~its use at recurrence. Its use is associated with better quality of~~ life ~~and delayed progression of symptoms~~. ~~However~~, ~~careful monitoring for adverse effects is necessary.~~		\|toxicity_explanation=The drug Procarbazine is considered quite toxic. This rating is based on the common side effects like hematological toxicity, which refers to potential harm to your blood cells, nausea, and neurological effects such as headache or dizziness. These side effects are relatively common and could significantly affect your day-to-day life. Remember, all treatments come with potential risks, and it's important to discuss these with your doctor.
			\|book_text=Temodar has also been combined with procarbazine (64). While the report of that study
	~~=== Avastin in Clinical Trials ===~~		did not include the PFS-6 statistic, it did report an unusually high percentage of tumor
	~~Two large randomized Phase III trials~~, ~~AVAglio~~ and ~~RTOG, evaluated the addition of Bevacizumab~~ to ~~the Stupp protocol for newly diagnosed glioblastoma~~. ~~In the AVAglio trial, median progression-free survival~~ (~~PFS~~) ~~was significantly longer for patients receiving Avastin (10~~.~~6 months) compared to~~ the ~~control group (6.2 months). However, overall survival (OS) was~~ not ~~significantly different (16.8 months vs. 16.7 months). Similarly,~~ the ~~RTOG trial reported a median~~ PFS of ~~10 months for the Avastin group versus 7.3 months for the control group~~, ~~with OS of 15.7 months for the Avastin group and 16.1 months for the control~~.		regressions, suggesting that this combination might be effective.
			\|overview=Procarbazine is an FDA-approved chemotherapy drug primarily used for treating glioblastoma, known for its effectiveness when combined with Temodar, as evidenced by a high percentage of tumor regressions. However, it carries a toxicity level of 4, with common side effects including hematological toxicity, nausea, and neurological effects that can significantly impact daily life.}}
	=~~== Quality of Life and Progression~~-~~Free Survival ===~~
	~~Both trials highlighted that while Avastin does not improve overall survival~~ when ~~administered~~ as ~~part~~ of ~~initial treatment, it can delay~~ tumor ~~progression and potentially improve the quality of life for patients~~. ~~Notably~~, ~~many control group patients received Avastin after tumor progression, making these studies~~ a ~~comparison~~ of ~~early versus delayed use of the drug.~~

	~~=== Future Research and Combinations ===~~
	~~Ongoing studies are exploring combinations of Bevacizumab~~ with ~~other agents,~~ including ~~targeted therapies~~, ~~immunotherapies~~, and radiosensitizers, to enhance its efficacy. These efforts aim to optimize the therapeutic window and potentially improve overall survival for glioblastoma patients.<ref>{{Cite web \|title=Clinical Trials of Bevacizumab in Glioblastoma \|url=https://www.ncbi.nlm.nih.~~gov \|publisher=PubMed \|accessdate=2024-08-12}}</ref>~~
	}}

Lazy at 16:28, 30 December 2024

2024-12-30T16:28:04Z

← Older revision		Revision as of 09:28, 30 December 2024
Line 1:		Line 1:
	{{TreatmentInfo		{{TreatmentInfo
	\|drug_name=Bevacizumab (Avastin)		\|drug_name=Bevacizumab (Avastin)
			\|overview=Bevacizumab, sold under the brand name Avastin, is a monoclonal antibody that inhibits vascular endothelial growth factor (VEGF). By targeting VEGF, Avastin reduces the blood supply to tumors, which can slow their growth. It is FDA-approved for the treatment of recurrent glioblastoma and is often combined with other therapies to manage this aggressive cancer.
	\|FDA_approval=Yes, for recurrent glioblastoma		\|FDA_approval=Yes, for recurrent glioblastoma
	\|used_for=~~Glioblastoma~~		\|used_for=Management of recurrent glioblastoma and investigational use in newly diagnosed glioblastoma as part of combination therapies
	\|clinical_trial_phase=Phase III		\|clinical_trial_phase=Phase III for glioblastoma
	\|common_side_effects=Hypertension, proteinuria, and ~~hemorrhage~~		\|common_side_effects=Hypertension, proteinuria, hemorrhage, gastrointestinal perforation, thromboembolic events, and wound healing complications
	\|OS_with=AVAglio trial: 16.8 months; RTOG trial: 15.7 months		\|OS_with=AVAglio trial: 16.8 months; RTOG trial: 15.7 months
			\|PFS_with=AVAglio trial: 10.6 months; RTOG trial: 10 months
			\|OS_without=AVAglio trial: 16.7 months; RTOG trial: 16.1 months
			\|PFS_without=AVAglio trial: 6.2 months; RTOG trial: 7.3 months
	\|usefulness_rating=4		\|usefulness_rating=4
	\|~~notes~~=~~Avastin improves PFS when used initially, but no significant benefit for overall survival compared to Avastin given at recurrence.~~		\|links=
	~~\|treatment_category=SOC Chemotherapy~~
	\|toxicity_level=3		\|toxicity_level=3
	\|toxicity_explanation=Bevacizumab has ~~an intermediate level of~~ toxicity. ~~Although~~ it ~~is a powerful medication against~~ glioblastoma, it can ~~have serious~~ side effects ~~including high blood pressure (~~hypertension), ~~presence of excess proteins in the urine (~~proteinuria), and ~~bleeding (hemorrhage)~~. ~~These~~ side effects ~~can impact your general health and daily activities. Therefore, this~~ treatment ~~needs regular monitoring by your health care provider and should be used with caution~~.		\|treatment_category=Other Chemotherapy and Cancer Drugs
	\|~~book_text~~=~~The most notable development~~ in ~~drug combinations has been the addition of the anti~~-		\|toxicity_explanation=Bevacizumab has a moderate toxicity profile. While it can extend progression-free survival and improve quality of life in glioblastoma patients, it can cause significant side effects. These include hypertension, proteinuria, bleeding, and rare but severe complications like gastrointestinal perforation and thromboembolic events. Regular monitoring and management of side effects are essential during treatment.
	~~angiogenic drug, Avastin (also known as bevacizumab),~~ to ~~the standard Stupp protocol~~.		\|notes=Bevacizumab has shown efficacy in improving progression-free survival in glioblastoma patients but does not significantly extend overall survival when compared to its use at recurrence. Its use is associated with better quality of life and delayed progression of symptoms. However, careful monitoring for adverse effects is necessary.
	~~As will be discussed later~~, ~~Avastin has FDA approval~~ for ~~the treatment of glioblastomas~~
	~~that have recurred or progressed after initial treatment. Several clinical trials have now~~
	~~investigated its combination with the gold standard Temodar protocol~~.

	~~Recently, there have been two~~ large randomized ~~phase~~ III ~~clinical~~ trials ~~comparing~~		=== Avastin in Clinical Trials ===
			Two large randomized Phase III trials, AVAglio and RTOG, evaluated the addition of Bevacizumab to the Stupp protocol for newly diagnosed glioblastoma. In the AVAglio trial, median progression-free survival (PFS) was significantly longer for patients receiving Avastin (10.6 months) compared to the control group (6.2 months). However, overall survival (OS) was not significantly different (16.8 months vs. 16.7 months). Similarly, the RTOG trial reported a median PFS of 10 months for the Avastin group versus 7.3 months for the control group, with OS of 15.7 months for the Avastin group and 16.1 months for the control.

	~~the Stupp protocol~~ and ~~the Stupp protocol +~~ Avastin, for ~~newly diagnosed~~ patients. ~~In the~~		=== Quality of Life and Progression-Free Survival ===
	~~first of these (70)~~, ~~known as the AVAglio trial~~, ~~median PFS was 10.6 months for those~~		Both trials highlighted that while Avastin does not improve overall survival when administered as part of initial treatment, it can delay tumor progression and potentially improve the quality of life for patients. Notably, many control group patients received Avastin after tumor progression, making these studies a comparison of early versus delayed use of the drug.
	~~receiving Avastin~~ versus ~~6.2 months for those receiving only~~ the ~~Stupp protocol, a~~
	~~statistically significant difference~~. ~~However, median overall survival was not different~~
	~~(16.8 months vs. 16.7 months). It should be noted that patients in the control group~~

			=== Future Research and Combinations ===
	~~typically received Avastin after tumor progression occurred, so that the comparison was~~		Ongoing studies are exploring combinations of Bevacizumab with other agents, including targeted therapies, immunotherapies, and radiosensitizers, to enhance its efficacy. These efforts aim to optimize the therapeutic window and potentially improve overall survival for glioblastoma patients.<ref>{{Cite web \|title=Clinical Trials of Bevacizumab in Glioblastoma \|url=https://www.ncbi.nlm.nih.gov \|publisher=PubMed \|accessdate=2024-08-12}}</ref>

	~~really between Avastin given early versus Avastin given only after recurrence. Additional~~
	~~results were that 72%~~ of ~~the Avastin group was alive at one year~~, ~~compared to 66% of the~~
	~~control group~~, ~~while two year survival was 34% vs. 30%.~~

	~~In the second of these large trials (71)~~, ~~conducted by the RTOG consortium~~, ~~the design~~
	~~was essentially similar~~ to ~~the AVAglio trial, as were the results~~. ~~Median PFS was 10~~
	~~months for those receiving Avastin vs. 7.3 months for~~ the ~~control group (again statistically~~
	~~significant), while median~~ overall survival ~~was 15.7 months~~ for ~~the Avastin group~~
	~~compared to 16~~.~~1 months for the control, a nonsignificant difference~~.

	~~The best interpretation of these results is that patients have a longer time without tumor~~
	~~progression, and presumably a better quality of life, when Avastin is used as part of the~~
	~~initial treatment~~. ~~However, there is no benefit for overall survival, when compared to~~
	~~withholding Avastin until recurrence is detected~~. ~~An additional feature of the results, not~~
	~~emphasized by the authors of the reports, is that the overall survival times were not~~
	~~notably better, and in many cases worse, than those obtained when the Stupp protocol is~~
	~~combined with various other treatment agents~~.
	}}		}}

Lazy at 16:26, 30 December 2024

2024-12-30T16:26:02Z

← Older revision		Revision as of 09:26, 30 December 2024
Line 8:		Line 8:
	\|usefulness_rating=4		\|usefulness_rating=4
	\|notes=Avastin improves PFS when used initially, but no significant benefit for overall survival compared to Avastin given at recurrence.		\|notes=Avastin improves PFS when used initially, but no significant benefit for overall survival compared to Avastin given at recurrence.
	\|treatment_category=~~Other~~ Chemotherapy ~~and Cancer Drugs~~		\|treatment_category=SOC Chemotherapy
	\|toxicity_level=3		\|toxicity_level=3
	\|toxicity_explanation=Bevacizumab has an intermediate level of toxicity. Although it is a powerful medication against glioblastoma, it can have serious side effects including high blood pressure (hypertension), presence of excess proteins in the urine (proteinuria), and bleeding (hemorrhage). These side effects can impact your general health and daily activities. Therefore, this treatment needs regular monitoring by your health care provider and should be used with caution.		\|toxicity_explanation=Bevacizumab has an intermediate level of toxicity. Although it is a powerful medication against glioblastoma, it can have serious side effects including high blood pressure (hypertension), presence of excess proteins in the urine (proteinuria), and bleeding (hemorrhage). These side effects can impact your general health and daily activities. Therefore, this treatment needs regular monitoring by your health care provider and should be used with caution.

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:35:02Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:35, 12 November 2024
Line 8:		Line 8:
	\|usefulness_rating=4		\|usefulness_rating=4
	\|notes=Avastin improves PFS when used initially, but no significant benefit for overall survival compared to Avastin given at recurrence.		\|notes=Avastin improves PFS when used initially, but no significant benefit for overall survival compared to Avastin given at recurrence.
	\|~~category~~=Other Chemotherapy and Cancer Drugs		\|treatment_category=Other Chemotherapy and Cancer Drugs
	\|toxicity_level=3		\|toxicity_level=3
	\|toxicity_explanation=Bevacizumab has an intermediate level of toxicity. Although it is a powerful medication against glioblastoma, it can have serious side effects including high blood pressure (hypertension), presence of excess proteins in the urine (proteinuria), and bleeding (hemorrhage). These side effects can impact your general health and daily activities. Therefore, this treatment needs regular monitoring by your health care provider and should be used with caution.		\|toxicity_explanation=Bevacizumab has an intermediate level of toxicity. Although it is a powerful medication against glioblastoma, it can have serious side effects including high blood pressure (hypertension), presence of excess proteins in the urine (proteinuria), and bleeding (hemorrhage). These side effects can impact your general health and daily activities. Therefore, this treatment needs regular monitoring by your health care provider and should be used with caution.

Lazy at 04:18, 28 March 2024

2024-03-28T04:18:57Z

@@ Line 11: / Line 11: @@
 |toxicity_level=3
 |toxicity_explanation=Bevacizumab has an intermediate level of toxicity. Although it is a powerful medication against glioblastoma, it can have serious side effects including high blood pressure (hypertension), presence of excess proteins in the urine (proteinuria), and bleeding (hemorrhage). These side effects can impact your general health and daily activities. Therefore, this treatment needs regular monitoring by your health care provider and should be used with caution.
 }}

Lazy at 16:56, 27 March 2024

2024-03-27T16:56:05Z

← Older revision		Revision as of 09:56, 27 March 2024
Line 9:		Line 9:
	\|notes=Avastin improves PFS when used initially, but no significant benefit for overall survival compared to Avastin given at recurrence.		\|notes=Avastin improves PFS when used initially, but no significant benefit for overall survival compared to Avastin given at recurrence.
	\|category=Other Chemotherapy and Cancer Drugs		\|category=Other Chemotherapy and Cancer Drugs
			\|toxicity_level=3
			\|toxicity_explanation=Bevacizumab has an intermediate level of toxicity. Although it is a powerful medication against glioblastoma, it can have serious side effects including high blood pressure (hypertension), presence of excess proteins in the urine (proteinuria), and bleeding (hemorrhage). These side effects can impact your general health and daily activities. Therefore, this treatment needs regular monitoring by your health care provider and should be used with caution.
	}}		}}

Lazy: Created page with "{{TreatmentInfo |drug_name=Bevacizumab (Avastin) |FDA_approval=Yes, for recurrent glioblastoma |used_for=Glioblastoma |clinical_trial_phase=Phase III |common_side_effects=Hypertension, proteinuria, and hemorrhage |OS_with=AVAglio trial: 16.8 months; RTOG trial: 15.7 months |usefulness_rating=4 |notes=Avastin improves PFS when used initially, but no significant benefit for overall survival compared to Avastin given at recurrence. |category=Other Chemotherapy and Cancer Dr..."

2024-03-24T13:12:00Z

Created page with "{{TreatmentInfo |drug_name=Bevacizumab (Avastin) |FDA_approval=Yes, for recurrent glioblastoma |used_for=Glioblastoma |clinical_trial_phase=Phase III |common_side_effects=Hypertension, proteinuria, and hemorrhage |OS_with=AVAglio trial: 16.8 months; RTOG trial: 15.7 months |usefulness_rating=4 |notes=Avastin improves PFS when used initially, but no significant benefit for overall survival compared to Avastin given at recurrence. |category=Other Chemotherapy and Cancer Dr..."

New page

{{TreatmentInfo
|drug_name=Bevacizumab (Avastin)
|FDA_approval=Yes, for recurrent glioblastoma
|used_for=Glioblastoma
|clinical_trial_phase=Phase III
|common_side_effects=Hypertension, proteinuria, and hemorrhage
|OS_with=AVAglio trial: 16.8 months; RTOG trial: 15.7 months
|usefulness_rating=4
|notes=Avastin improves PFS when used initially, but no significant benefit for overall survival compared to Avastin given at recurrence.
|category=Other Chemotherapy and Cancer Drugs
}}